SCHEMBL6001834

SCHEMBL6001834

c1ccc2c(Oc3ccc4c(c3)OCO4)nc(-c3ccncc3)nc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.62
MAPT P10636 7/20 0.61
LMNA P02545 5/20 0.61
MAPK1 P28482 5/20 0.61
POLB P06746 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
CYP1A2 P05177 4/20 0.54
CYP3A4 P08684 4/20 0.54
CYP2D6 P10635 4/20 0.54
CYP2C19 P33261 4/20 0.54
HSD17B10 Q99714 4/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
TP53 P04637 3/20 0.54
CYP2C9 P11712 2/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
ABCG2 Q9UNQ0 5/20 0.53
NPC1 O15118 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6001935 0.88 LMNA (0.55) KDM4EMAPTLMNAMAPK1CYP1A2
SCHEMBL6001863 0.82 GBA1 (0.52) KDM4EMAPTLMNAMAPK1POLB
SCHEMBL5999882 0.81 LMNA (0.59) KDM4EMAPTLMNAMAPK1POLB
SCHEMBL6001899 0.80 MAPT (0.55) KDM4EMAPTLMNAMAPK1POLB
SCHEMBL1083987 0.77 KDM4E (0.81) KDM4EMAPTLMNAMAPK1POLB
SCHEMBL22201446 0.75 ALDH1A1 (0.80) KDM4EMAPTLMNAMAPK1POLB
SCHEMBL30969595 0.74 HPGD (0.57) KDM4EMAPTLMNAMAPK1POLB
SCHEMBL6001437 0.74 KDM4E (0.71) KDM4EMAPTLMNAMAPK1POLB
SCHEMBL1083765 0.70 MAPT (1.00) KDM4EMAPTLMNAMAPK1POLB
SCHEMBL16404335 0.68 ABCG2 (0.74) KDM4EMAPTLMNAMAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060128702-A1 Heterocyclic and bicyclic compounds, compositions and methods REDDY US THERAPEUTICS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128702-A1 Heterocyclic and bicyclic compounds, compositions and methods HPSE, ENGASE, UGCG KDM4E 2893/4885MAPT 4070/4885LMNA 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.